SEC Form 4 · accession 0001640069-26-000002
Stoke Therapeutics, Inc. · STOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer Burstein
Director
Period of report
Jun 3, 2026
Accepted (ET)
Jun 5, 2026 · 4:24 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001623526
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy)F1 | $29.46 | Jun 3, 2026 | A | 17,786 | A | — | Jun 2, 2036 | Common Stock | 17,786 | 17,786 | D |
Explanation of responses
- F1The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.